Bone density loss over time in postmenopausal
women. The expected effect of antiresorptive therapy
(Rx) is to stabilize bone density as inhibition of resorption ultimately leads to inhibition of formation.
Formation-stimulating therapy (anabolic) should lead to
further increases in bone density. Initiation of therapy
sooner rather than later should predictably help prevent
further loss and decrease the risk of fracture.